Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Anbio Biotechnology seeks IPO funding to expand in the IVD market. Discover why NNNN stock’s potential is tempered by ...

Achieving biotech sovereignty will reduce dependency on foreign nations for critical products and technologies, ensuring ...

Mohali, is inviting applications for its prestigious PhD program in Biotechnology, commencing in January 2025, with research ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, January 6: Ashford ...

Anbio Biotechnology filed for a 1.6 million-share initial public offering with the Securities and Exchange Commission. The company said Tuesday it expects the IPO to price between $5 and $6 per share, ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Biotechnology, a transformative field at the crossroads of science and technology, continues to revolutionize industries ...

The year 2025 will witness India assuming critical role in the global biotechnology revolution, and the first Bio-E3 policy ...

University of York spin-out, Cizzle Biotechnology, has announced that it has appointed a new chief scientific officer (CSO).

Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.